Therapy Areas: Oncology
Mundipharma Licenses Intrarosa (Prasterone) in MEA Region
23 May 2018 - - Dubai, UAE-based pharmaceutical company Mundipharma has been granted the commercial rights to Intrarosa (Prasterone) in the Middle East and Africa (MEA region) as part of an agreement signed between Mundipharma and Endoceutics, Inc., the company said.
A unique non-estrogen prescription therapy, Intrarosa, has been approved by the US Food and Drug Administration and by the European Medical Agency, for the treatment of the most bothersome symptom of vulvovaginal atrophy, due to menopause, known as dyspareunia.
Intrarosa (Prasterone) has been developed for the treatment of women experiencing moderate to severe dyspareunia, which is an outcome of vulvovaginal atrophy, that occurs due to menopause. Intrarosa is a unique non-estrogen product that is administered locally in order to exert an action limited to the vagina.
Intrarosa was approved by the FDA in the US and by EMA for all countries of Europe. As the unique intracellular precursor of sex steroids in women, Intrarosa (Prasterone) is transformed into androgens and estrogens inside the vaginal cells without any biologically significant increase in estrogens or androgens found in the patient's blood.
Mundipharma is a network of independent associated companies committed to providing affordable treatment, and focussing on specialist therapy areas including analgesia, oncology, ophthalmology, respiratory, specialty care, and consumer healthcare.
The company has an established business presence in six continents, innovative research and development, and eight manufacturing facilities around the world.
Login
Username:

Password: